Gatifloxacin belongs to the fourth generation of quinolone antibacterial drugs. It is a racemic compound of 8-methoxyfluoroquinolone. It has a broad spectrum of activity against Gram-negative and Gram-positive microorganisms in vitro. Its R- and S-enantiomers have the same antibacterial activity. The antibacterial effect is achieved by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes.

It is a new type of defense factor-enhanced gastritis and gastric ulcer therapeutic agent. It has an inhibitory effect on various experimental ulcers, a therapeutic and preventive effect on experimental gastritis, and a preventive effect on acute gastric mucosal lesions. It can enhance the blood flow of the gastric mucosa and promote tissue repair. Unlike H2-receptor antagonists, it has no effect on gastric acid secretion, but enhances the defense factors of the gastric mucosa and promotes the repair of gastric ulcer sites.

Synthetic nucleoside antiviral drugs, which have inhibitory effects on herpes simplex virus type I (HSV-1), type H (HSV-2) and varicella-zoster virus (VZV) in vivo and in vitro. Cell culture results show that this product has the strongest inhibitory effect on HSV-1 virus, followed by HSV-2 and VZV virus. It is converted into acyclovir monophosphate by virus-encoded thymidine kinase (TK), and further converted into diphosphate and triphosphate, thus terminating herpes virus DNA replication.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

It inhibits bacterial DNA replication, transcription and repair processes by inhibiting bacterial DNA gyrase and topoisomerase IV. It has antibacterial activity against the following microorganisms: Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae), Gram-negative bacteria (such as Escherichia coli, Haemophilus influenzae and parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Neisseria gonorrhoeae, Proteus mirabilis) and other microorganisms (such as Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae).